Sino Biopharm unit CTTQ to present phase 3 APEX-Breast01 data for TQB2102 at ESMO 2026

CTTQ says it will present APEX-Breast01 phase 3 data for TQB2102 in HER2-low recurrent or metastatic breast cancer at ESMO 2026 in Madrid on Oct. 23, 2026, plus an update on its TQB2102 phase 2 gastric and gastroesophageal junction study.